{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'AE and SAE Recording', 'When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (eg,', 'hospital progress notes, laboratory reports, and diagnostics reports) related to the event.', 'The Investigator will then record all relevant AE/SAE information in the CRF. Each event must be', 'recorded separately.', \"It is not acceptable for the Investigator to send photocopies of the subject's medical records to IQVIA\", 'Biotech Safety in lieu of completion of the AE/SAE CRF page.', 'There may be instances when copies of medical records for certain cases are requested by IQVIA', 'Biotech Safety. In this case, all subject identifiers, with the exception of the subject number, will be', 'redacted on the copies of the medical records before submission to IQVIA Biotech Safety.', 'The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or', 'other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will', 'be documented as the AE/SAE.', 'Assessment of Intensity', 'The Investigator will make an assessment of intensity for each AE and SAE reported during the study and', 'assign it to 1 of the following categories:', 'Mild: An event that is easily tolerated by the subject, causing minimal discomfort and not interfering', 'with everyday activities.', 'Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities.', 'Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not', 'be confused with a SAE. Severe is a category utilized for rating the intensity of an event; and both AEs', 'and SAEs can be assessed as severe.', \"An event is defined as 'serious' when it meets at least 1 of the predefined outcomes as described in the\", 'definition of an SAE, NOT when it is rated as severe.', 'Assessment of Causality', 'The Investigator is obligated to assess the relationship between study treatment and each occurrence of', 'each AE/SAE. The AE must be characterized as unrelated, unlikely to be related, possibly related,', 'probably related, or unknown (unable to judge).', '\"Probably related\" conveys that there are facts, evidence, and/or arguments to suggest a', 'causal relationship, rather than a relationship cannot be ruled out.', '\"Possibly related\" suggests that the association of the AE with the study treatment is', 'unknown; however, the AE is not reasonably supported by other conditions.', '\"Unlikely to be related\" suggests that only a remote connection exists between the study', 'treatment and the AE. Other conditions, including chronic illness, progression or expression', 'of the disease state or reaction to concomitant therapy, appear to explain the reported AE.', '\"Unrelated\" is used if there is not a reasonable possibility that the study treatment caused the', 'AE.', 'All efforts should be made to classify the AE according to the above categories. The category', '\"unknown\" (unable to judge) may be used only if the causality is not assessable, eg, because', 'of insufficient evidence, conflicting evidence, conflicting data, or poor documentation.', 'The Investigator will use clinical judgment to determine the relationship.', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well', 'as the temporal relationship of the event to study treatment administration will be considered and', 'investigated.', '66']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', \"The Investigator will also consult the Investigator's Brochure (IB) and/or Product Information, for\", 'marketed products, in his/her assessment.', 'For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed the', 'AE/SAE and has provided an assessment of causality.', 'There may be situations in which an SAE has occurred, and the Investigator has minimal information', 'to include in the initial report to IQVIA Biotech Safety. However, it is very important that the', 'Investigator always make an assessment of causality for every event before the initial transmission of', 'the SAE data to IQVIA Biotech Safety.', 'The Investigator may change his/her opinion of causality in light of follow-up information and send an', 'SAE follow-up report with the updated causality assessment.', 'The causality assessment is one of the criteria used when determining regulatory reporting', 'requirements.', 'Follow-Up of AEs and SAEs', 'The Investigator is obligated to perform or arrange for the conduct of supplemental measurements', 'and/or evaluations as medically indicated or as requested by IQVIA Biotech Safety to elucidate the', 'nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory', 'tests or investigations, histopathological examinations, or consultation with other health care', 'professionals.', 'If a subject dies during participation in the study or during a recognized follow-up period, the', 'Investigator will provide IQVIA Biotech Safety with a copy of any postmortem findings including', 'histopathology.', 'New or updated information will be recorded in the originally completed eCRF.', 'The Investigator will submit any updated SAE data to the Sponsor/IQVIA Biotech Safety within 24', 'hours of receipt of the information.', 'Reporting of SAEs', 'SAE Reporting to IQVIA Biotech Safety via Paper CRF', 'E-mail transmission of the SAE paper CRF is the preferred method to transmit this information to', 'IQVIA Biotech Safety with Facsimile transmission as back-up method.', 'In rare circumstances and in the absence of e-mail/facsimile equipment, notification by telephone is', 'acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.', 'Initial notification via telephone does not replace the need for the Investigator to complete and sign the', 'SAE eCRF pages within the designated reporting time frames.', 'Contacts for SAE reporting can be found in Investigator Study Binder. All SAEs must also be reported', 'to IQVIA Biotech Safety within 24 hours of first awareness of the event. A paper SAE Report Form', 'should be completed and submitted via e-mail to Safety-Inbox.Biotech@IQVIA.com or faxed to +1- -', '919-313-1412.', '67']\n\n###\n\n", "completion": "END"}